Arca
Skip to content
Tools
Tools

TLR8: Toll-like receptor 8

Endosomal receptor that plays a key role in innate and adaptive immunity.

  • Drugs that act on it: 7
  • Approved: 0
  • In phases 1 to 3: 7
  • Sponsors: 7

Who is on it, and how far along

Every drug ChEMBL records acting on TLR8, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 6
  • Other 1

Approved0

    Phase 30

      Phase 27

      • Resiquimod
      • Enpatoran
      • Telratolimod
      • Afimetoran
      • Bazlitoran
      • Motolimod
      • Selgantolimod

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 7 act as: Toll-like receptor 8 agonist; the rest name their own mechanism.
        ResiquimodPhase 2SURGE TherapeuticsSmall moleculeAgonist6
        EnpatoranPhase 2Merck KGaASmall moleculeAntagonistToll-like receptor 8 antagonist4
        TelratolimodPhase 2MedImmune LLCSmall moleculeAgonist4
        AfimetoranPhase 2Beeline Medicines CorporationSmall moleculeInhibitorToll-like receptor 8 inhibitor2
        BazlitoranPhase 2Idera PharmaceuticalsOtherAntagonistToll-like receptor 8 antagonist0
        MotolimodPhase 2Bristol-Myers SquibbSmall moleculeAgonist0
        SelgantolimodPhase 2Gilead SciencesSmall moleculeAgonist0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
        Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusAfimetoranPhase 2 / Phase 3RecruitingBeeline Medicines CorporationOct 19, 2026
        A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]EnpatoranPhase 3RecruitingEMD Serono Research & Development Institute, Inc.Sep 25, 2026
        A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)EnpatoranPhase 3RecruitingEMD Serono Research & Development Institute, Inc.Jan 21, 2026
        A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEnpatoranPhase 3RecruitingEMD Serono Research & Development Institute, Inc.Jan 12, 2026
        Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)ResiquimodPhase 1 / Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesDec 29, 2025
        HF50 in HER-2 Positive and Low-expression Advanced Solid TumorsResiquimodEarly phase 1RecruitingHighField Biopharmaceuticals CorporationFeb 12, 2025
        Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good HealthTelratolimodPhase 1RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)Jan 28, 2025
        Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But UninfectedTelratolimodPhase 1Not yet recruitingHIV Vaccine Trials NetworkSep 26, 2024
        Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)ResiquimodNot applicableRecruitingAkhilesh JhaJul 5, 2024
        Study of STM-416p Administered to Patients Undergoing Radical ProstatectomyResiquimodPhase 1RecruitingSURGE TherapeuticsJun 10, 2024
        Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.TelratolimodPhase 1Active, not recruitingNational Institute of Allergy and Infectious Diseases (NIAID)Mar 27, 2024
        Nasal Immune Challenge StudyResiquimodNot applicableActive, not recruitingCambridge University Hospitals NHS Foundation TrustSep 1, 2023
        Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIVTelratolimodPhase 1Active, not recruitingNational Institute of Allergy and Infectious Diseases (NIAID)Jun 15, 2023
        A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder CancerResiquimodPhase 1 / Phase 2RecruitingSURGE TherapeuticsFeb 2, 2023
        The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)EnpatoranPhase 2Active, not recruitingMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanySep 14, 2022
        A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)AfimetoranPhase 2Active, not recruitingBeeline Medicines CorporationMay 20, 2021

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Immunodeficiency 98 with autoinflammation, X-linked0.74
        • Systemic autoinflammation0.37
        • Autoimmune disorder of central nervous system0.17
        • Neoplasm0.12
        • Chronic hepatitis B virus infection0.11
        • Hepatitis B virus infection0.11
        • Common wart0.11
        • Primary cutaneous T-cell non-Hodgkin lymphoma0.11

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5805, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9NR97, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.